The Tdap vaccine has a strong safety record backed by decades of use and ongoing surveillance. Reviews of adverse event reports by the CDC and FDA have found no unexpected safety concerns for the general population, pregnant women, or adults over 65. Like any vaccine, it can cause temporary side effects, but serious reactions are extremely rare.
What Common Side Effects Look Like
The most frequent side effects are mild and short-lived. Pain, redness, or swelling at the injection site are the reactions you’re most likely to notice, typically appearing within a day or two and resolving on their own. Some people also experience low-grade fever, headache, fatigue, or body aches. These reactions reflect your immune system responding to the vaccine, not a sign that something has gone wrong.
Tdap is formulated with lower amounts of active ingredients than the childhood version (DTaP), which is one reason side effects tend to be mild in teens and adults. For context, Tdap contains roughly 2 to 2.5 units of diphtheria component compared to 15 to 25 units in the childhood formulation, and similarly reduced amounts of the pertussis components.
Safety During Pregnancy
Tdap is recommended during each pregnancy, ideally between weeks 27 and 36, so the mother can pass protective antibodies to the baby before birth. This timing matters because newborns are most vulnerable to severe whooping cough and too young to be vaccinated themselves.
A large study of more than 118,000 pregnancies found no association between Tdap vaccination and preterm birth, with an adjusted comparison showing essentially identical risk between vaccinated and unvaccinated groups. The study also looked at a range of newborn outcomes, including low Apgar scores, respiratory distress, neonatal sepsis, and newborn seizures. None showed a statistically significant increase in the vaccinated group. Rates of chorioamnionitis, an infection of the membranes surrounding the baby, were also no different between groups.
Rare Serious Reactions
Severe allergic reactions (anaphylaxis) can occur with virtually any vaccine or medication but are very uncommon with Tdap. These reactions typically happen within minutes of vaccination, which is why you’re asked to wait briefly at the clinic afterward.
One concern people sometimes raise is Guillain-Barré syndrome, a condition where the immune system temporarily attacks the nerves. A large-scale analysis covering more than 30 million person-years of observation found no evidence of increased GBS risk following any vaccination, including tetanus-containing vaccines. As a precaution, if someone has developed GBS within six weeks of a previous tetanus-containing vaccine, future doses are deferred, though this scenario is uncommon.
Aluminum in Tdap
Tdap contains a small amount of aluminum, about 0.33 to 0.39 milligrams per dose, which helps strengthen the immune response. This amount is tiny compared to what you encounter through food and water daily. A pharmacokinetic study found that the total aluminum burden from vaccines given in the first year of life, combined with dietary exposure, stays well within safe limits even for small infants.
Blood and hair aluminum levels in vaccinated children are indistinguishable from those in unvaccinated individuals, and studies have found no correlation between aluminum from vaccines and developmental outcomes. The World Health Organization’s Global Advisory Committee on Vaccine Safety has reviewed the evidence and found no health risks warranting changes to vaccine policy. In children, aluminum-containing vaccines are associated with slightly more redness and firmness at the injection site compared to aluminum-free vaccines, but not with serious adverse events.
Who Should Not Get Tdap
There are a few specific situations where Tdap should be avoided or delayed:
- Severe allergic reaction: Anyone who has had anaphylaxis after a previous dose or to a component of the vaccine should not receive it again.
- Encephalopathy after a prior dose: If someone experienced coma, prolonged seizures, or a decreased level of consciousness within seven days of a previous tetanus or pertussis-containing vaccine, and no other cause was found, Tdap is contraindicated.
- Arthus-type hypersensitivity: This is a severe local reaction involving significant swelling after a previous tetanus or diphtheria-containing vaccine. If this has occurred, vaccination should be deferred until at least 10 years have passed since the last dose.
- Unstable neurological conditions: People with progressive neurological disorders or uncontrolled seizures should wait until their condition is stabilized before receiving Tdap.
- Moderate or severe acute illness: If you’re currently sick with something beyond a mild cold, it’s generally best to wait until you recover.
How Tdap Safety Is Monitored
The Tdap vaccine doesn’t just get approved and forgotten. The CDC and FDA jointly run the Vaccine Adverse Event Reporting System (VAERS), an early warning system that continuously scans for potential safety signals. Any healthcare provider or patient can submit a report, and unusual patterns trigger deeper investigation. These ongoing reviews have consistently confirmed Tdap’s safety profile across all recommended groups.
Recommended Schedule
Adults need one dose of Tdap if they haven’t previously received it, followed by a tetanus booster (either Td or Tdap) every 10 years. Pregnant individuals get one dose during each pregnancy. You may also receive a dose for wound management if your tetanus protection isn’t up to date. The schedule is straightforward: once you’ve had your initial Tdap, you just need to keep up with boosters roughly once a decade.